Marinomed Biotech AG

  • WKN: A2N9MM
  • ISIN: ATMARINOMED6
  • Land: Österreich

Nachricht vom 03.11.2021 | 07:45

Solv4U: Marinomed launches new business area enabling the development of innovative formulations in technology partnerships

DGAP-News: Marinomed Biotech AG / Key word(s): Market launch
03.11.2021 / 07:45
The issuer is solely responsible for the content of this announcement.

Solv4U: Marinomed launches new business area enabling the development of innovative formulations in technology partnerships

  • Solv4U is a new business area that opens Marinomed's proprietary Marinosolv technology for external partners in technology partnerships
  • Solv4U is designed to improve the solubility and bioavailability of compounds hardly soluble in aqueous formulations with the potential to reduce the dose of the active pharmaceutical ingredient (API)
  • Solv4U increases the precision of a therapy, allows targeted administration of drugs and contributes to sustainability by reducing the amount of administered drugs
  • Solv4U offers a clinically proven formulation platform and is suited for local and systemic administration
  • Solv4U will be presented at CPhI from 9-11 November 2021 in Milan (Italy) as well as virtually

Korneuburg, Austria, 03 November 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today the launch of Solv4U, a new business area enabling the development of innovative formulations in technology partnerships based on the clinically proven Marinosolv platform. Solv4U is designed to support clients with formulation development to increase both solubility and bioavailability of hydrophobic small molecules and peptides in all stages of drug discovery. It has been clinically shown that Marinosolv allows a pronounced reduction in the amount of an API in a formulation with an improved therapeutic effect suggesting a more targeted, more precise, and more sustainable treatment compared to existing options.

"We are excited that with our new business area, Solv4U, the advantages of Marinosolv are now available for pharma- and biotech customers through technology partnerships. High bioavailability is a key requirement in drug development and with Solv4U partnerships, we can provide a clinically validated solution," said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed.

"Solv4U will contribute to a successful drug development at all stages with novel targeted formulations enabling more precise and more sustainable drugs with patent protection," said Dr. Susanne Bach, Senior Manager BD&L for Solv4U. "Solv4U partnerships may help to improve and facilitate both local or systemic therapies based on Marinomed's expertise gained from internal projects and studies performed for clients."

The development of hydrophobic highly active compounds is often hampered by their low local and systemic bioavailability resulting in excessively high dosing of the drug to compensate for the lack of efficacy. Solv4U partnerships address this inherent challenge in drug development and rely on a clinically proven technology. Formulations based on Marinosolv are well-tolerated when administered locally or systemically allowing various applications in different indications.

The patented Marinosolv technology offered to Solv4U partners is based on micelles and is customized for individual compounds to achieve an optimal formulation.

For more information on Solv4U, visit the new Solv4U website, get in touch with Marinomed directly, or meet us, in person or virtually, at CPhI:

CPhI worldwide(R) 2021
9-11 November 2021 - Fiera Milano, Milan, Italy
25 October - 19 November 2021, Online Conference & Networking
The company's exhibition stand #3F71 is located on the ICSE General Floor. Marinomed will also be glad to receive virtual partnering requests via CPhI-online.

Contact for Solv4U:

Susanne Bach, PhD, Senior Manager BD&L
Marinomed Biotech AG, Hovengasse 25, 2100 Korneuburg, Austria
E-Mail: bd@marinomed.com
Tel: +43 2262 90300
 

About Marinosolv(R):
Marinosolv(R) is an innovative technology platform that enables the solubilization and enhances the bioavailability of small molecules and peptides that are hardly soluble in aqueous formulations. Consequently, new treatments of a multitude of diseases can be envisaged. The use of the Marinosolv(R) technology can facilitate efficient drug delivery with a low systemic off-target activity. Existing drugs and off-patent active ingredients can be improved and re-patented as part of new formulations using Marinosolv(R). Under the brand Solv4U, Marinomed provides Marinosolv(R) formulation development in technology partnerships for active ingredients at all stages of drug discovery and lifecycle extension. For more information on Marinosolv(R), please visit https://www.marinosolv.com/en. Information about Solv4U can be found here: https://www.solv4u.com. Scientific publications on Marinosolv(R) can be accessed at https://www.marinosolv.com/en/publications.

About Marinomed Biotech AG
Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics. The company is listed on the Prime Market of the Vienna Stock Exchange. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv(R) technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. The Carragelose(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose(R) is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries. Marinomed(R), Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. Further information is available at https://www.marinomed.com.


For further inquiries contact:

Marinomed Biotech AG
Lucia Mayr-Harting, PR
Hovengasse 25, 2100 Korneuburg, Austria                  
T +43 2262 90300-158
E-mail: pr@marinomed.com
http://www.marinomed.com
International Media Contact
MC Services AG
Dr. Brigitte Keller, Dr. Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
E-mail: marinomed@mc-services.eu
 

Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.



03.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Events im Fokus

Termine 2022

1./2. Juni 2022: Fachkonferenz Immobilien & Software | IT

13./14. Juli 2022: Fachkonferenz Beteiligungsgesellschaften & Consumer/Leisure

12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie

Aktueller Webcast

Novem Group S.A.

FY 2021/22 Preliminary Results

02. Juni 2022

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

25. Mai 2022